Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326843 · ClinicalTrials.gov registry record · Phase 3
Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
A Phase 3 study, sponsored by Sobi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT03326843: Clinical Trial Phase 3 study, sponsored by Sobi.
NCT03326843 is a Phase 3 study that was terminated before completion, run by Sobi. The registered enrollment target is 4 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03326843, a Phase 3 study, was terminated before completion, sponsored by Sobi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding.
Primary Outcome
Proportion of subjects that achieve a platelet count \>100 x 10\^9 platelets/L on procedure day
Interventions
- DRUG Avatrombopag 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2019-02-25 |
| Phase | Phase 3 |
Why NCT03326843 stopped before completion
NCT03326843 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Avatrombopag 60 mg is the first listed.
NCT03326843 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03326843 about?
NCT03326843 is a clinical study titled "Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure". Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding.
What is the current status of trial NCT03326843?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2018-03-26. Estimated completion is 2019-02-25.
What interventions are being tested in trial NCT03326843?
The interventions under investigation include: Avatrombopag 60 mg (DRUG).
Who is sponsoring clinical trial NCT03326843?
This trial is sponsored by Sobi, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03326843's enrollment target sits among peer trials
4 1998th of 2000 higher than 2 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI